Anthropic has acquired Coefficient Bio, a stealth biotech AI startup founded eight months ago, in an all-stock deal worth approximately $400 million. The deal, first reported by The Information and confirmed by TechCrunch, brings a team of fewer than 10 people into Anthropic’s healthcare and life sciences division, where they will build AI agents for drug discovery, clinical trial planning, and regulatory workflows.
Coefficient Bio’s co-founders, Samuel Stanton and Nathan C. Frey, both came from Prescient Design, Genentech’s computational drug discovery unit. Frey led a group working on biological foundation models and biomolecule design, with more than 20 publications in journals including Science Advances and Nature Machine Intelligence, according to The Next Web. The startup had no publicly known product and no disclosed revenue. It had built a platform for AI-drafted drug R&D plans, clinical regulatory strategies, and drug candidate identification.
Where the Team Lands
The Coefficient Bio team will join the Health Care Life Sciences group led by Eric Kauderer-Abrams. When Anthropic launched Claude for Life Sciences in October 2025, Kauderer-Abrams told CNBC: “We want a meaningful percentage of all of the life science work in the world to run on Claude, in the same way that that happens today with coding,” as reported by TNW. Claude for Life Sciences integrates with PubMed, Benchling, ClinicalTrials.gov, and 10x Genomics for tasks ranging from literature synthesis to regulatory submissions, according to PYMNTS.
Coefficient Bio’s specialization in protein design and biomolecule modeling gives Anthropic domain-specific expertise that a general-purpose research assistant cannot replicate. Dimension, the venture firm that held roughly half the company, is reporting a 38,513% internal rate of return on its investment, per TNW.
The Agent Strategy Signal
The acquisition maps to a broader pattern in Anthropic’s recent moves. In the same week, Anthropic is cutting off third-party agent platforms like OpenClaw from Claude subscriptions (effective April 4 at 3 PM ET), forcing them onto API billing. The contrast is stark: Anthropic is restricting how external builders use Claude as a general-purpose agent backbone while investing $400 million to build its own specialized agent stack in healthcare.
Anthropic is not alone in the space. Google DeepMind’s Isomorphic Labs has AI-designed drug candidates now entering clinical trials, and Nvidia announced a $1 billion, five-year partnership with Eli Lilly in January for AI-accelerated drug discovery, as noted by TNW. For builders deploying agents on Anthropic’s models: the company is increasingly becoming a potential competitor in high-value verticals, not just a model provider.